MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ahj.2012.09.009

Медицинская библиотека · American heart journal · 2012

Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: rationale and design of a large-scale, randomized, multicenter study.

Feres Fausto, Costa Ricardo A, Bhatt Deepak L, Leon Martin B, Botelho Roberto V, King Spencer B, de Paula J Eduardo T, Mangione José A, Salvadori Décio, Gusmão Marcos O, Castello Hélio, Nicolela Eduardo, Perin Marco A, Devito Fernando S, Marin-Neto J Antônio, Abizaid Alexandre

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Current recommendations for antithrombotic therapy after drug-eluting stent (DES) implantation include prolonged dual antiplatelet therapy (DAPT) with aspirin and clopidogrel ≥12 months. However, the impact of such a regimen for all patients receiving any DES system remains unclear based on scientific evidence available to date. Also, several other shortcomings have been identified with prolonged DAPT, including bleeding complications, compliance, and cost. The second-generation Endeavor zotarolimus-eluting stent (E-ZES) has demonstrated efficacy and safety, despite short duration DAPT (3 months) in the majority of studies. Still, the safety and clinical impact of short-term DAPT with E-ZES in the real world is yet to be determined.

METHODS

The OPTIMIZE trial is a large, prospective, multicenter, randomized (1:1) non-inferiority clinical evaluation of short-term (3 months) vs long-term (12-months) DAPT in patients undergoing E-ZES implantation in daily clinical practice. Overall, 3,120 patients were enrolled at 33 clinical sites in Brazil. The primary composite endpoint is death (any cause), myocardial infarction, cerebral vascular accident, and major bleeding at 12-month clinical follow-up post-index procedure.

CONCLUSIONS

The OPTIMIZE clinical trial will determine the clinical implications of DAPT duration with the second generation E-ZES in real-world patients undergoing percutaneous coronary intervention.

Для цитирования: Feres Fausto, Costa Ricardo A, Bhatt Deepak L, Leon Martin B, Botelho Roberto V, King Spencer B, de Paula J Eduardo T, Mangione José A, Salvadori Décio, Gusmão Marcos O, Castello Hélio, Nicolela Eduardo, Perin Marco A, Devito Fernando S, Marin-Neto J Antônio, Abizaid Alexandre. Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: rationale and design of a large-scale, randomized, multicenter study.. American heart journal. 2012. DOI: 10.1016/j.ahj.2012.09.009.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.